Navigation Links
U.S. Army and Navy Purchase Over 10,000 New Beretta M9 Pistols
Date:9/10/2007

ACCOKEEK, Md., Sept. 10 /PRNewswire/ -- Beretta U.S.A. Corp. announced today the receipt of purchase orders from the U.S. Army and U.S. Navy for a total of 10,576 M9 pistols (5,969 for the Army, 4,607 for the Navy). The purchase orders were issued against a multi-year contract between Beretta U.S.A. and the U.S. Army, which serves as executive purchasing agent of the M9 pistol for all branches of the U.S. Armed Forces.

"We are always honored to be given the opportunity to serve the U.S. Armed Forces by supplying the Beretta M9 pistol," noted Jeff Reh, Vice-General Manager for Beretta U.S.A. Corp. "The Beretta M9 pistol remains the most reliable and well-tested handgun in the U.S. military inventory, with tests resulting in an average of only one malfunction every 20,500 rounds fired." Beretta U.S.A. Corp., manufacturer of the Beretta M9 pistol, employs over 330 employees and manufactures the sidearm at its factory in Accokeek, Maryland.

Beretta U.S.A. Corp. has supplied the Beretta M9 pistol as the standard sidearm for the U.S. Armed Forces since 1985.

In 2005, Beretta U.S.A. Corp. received 13 contracts for M9 pistols and component parts from the U.S. Army and U.S. Marine Corps. Many of the U.S. Army contracts were multi-year contracts lasting five years, from which over 31 million dollars in purchase orders have since been issued to Beretta U.S.A. Corp.

Beretta, established in 1526, is the oldest industrial dynasty in the world tracing its roots through 16 generations of continuous family ownership. Firearms bearing the Beretta name have been sold for almost 500 years. Beretta USA Corp. was founded in 1977 and supplies the standard sidearm to the U.S. Armed Forces. Today Beretta manufactures, distributes and markets a complete line of firearms, accessories and apparel. Beretta also owns and operates six retail Beretta Gallery stores worldwide. For additional information visit http://www.berettausa.com.


'/>"/>
SOURCE Beretta U.S.A. Corp.
Copyright©2007 PR Newswire.
All rights reserved

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/11/2017)... 2017 Intoxalock, a leading ignition interlock provider, ... its patent-pending calibration device. With this new technology, Intoxalock ... upload data logs and process repairs at service center ... "Fighting drunk driving through the application of cutting-edge technologies ... but also for the customer who can get back ...
(Date:1/6/2017)... NEWARK, Calif. , Jan. 5, 2017  Delta ... introduced its iris scanning technology for automotive at CES® ... GNTX ) to demonstrate the use of ... to identify and authenticate the driver in a car, ... automobiles during the driving experience. Delta ID ...
(Date:12/22/2016)... , Dec. 20, 2016  As part of its ... the leading personal genetics company, recently released its latest children,s ... . The book focuses on the topics of inheritance and ... Science Standards (NGSS) taught in elementary school classrooms in the ... a series by illustrator Ariana Killoran , whose previous ...
Breaking Biology News(10 mins):
(Date:1/17/2017)... West Point, IA (PRWEB) , ... January 17, ... ... approval from China for Balance™ GT soybeans. The new Balance™ GT Soybean Performance ... tolerance to glyphosate and isoxaflutole, the active ingredient in the new Balance® Bean ...
(Date:1/17/2017)... , Jan. 17, 2017   Pulmatrix, Inc . ... company developing innovative inhaled therapies to address serious pulmonary ... fungal infections in the lungs of CF patients, PUR1900, ... (QIDP) by the U.S. Food & Drug Administration. ... designed to speed the development of novel drugs against ...
(Date:1/17/2017)... ... January 17, 2017 , ... ... the North American Spine Society (NASS)1 demonstrate high fusion rates at 6 ... when PEEK-OPTIMA™ HA Enhanced is used for interbody-fusion devices. The implantable high-performance ...
(Date:1/17/2017)... , Jan. 17, 2017  Protagonist Therapeutics, ... that it has initiated a global Phase 2b ... oral peptide that targets alpha4beta7 integrin. The aim ... is to evaluate the safety/tolerability and efficacy of ... with moderate to severe active disease. ...
Breaking Biology Technology: